Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Solid Biosciences Inc.NASDAQ: SLDB
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$57.31M, compared with -$40.05M a year earlier. Trailing-twelve-month operating income was -$196.46M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 10 analysts of -$144.05M (+19.6%) for the fiscal year ending Dec 2026, a step up from the -38.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$57.31M-16.0% QoQ
- Last fiscal yearDec 2025
- -$179.21M-38.1% YoY
- LTMMar 2026
- -$196.46M-37.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -43.1% | — | — |
| 1 year | -38.1% | +19.6% | +57.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (179.21M) USD
- Year-over-year change
- -38.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (179.21M) | -38.1% |
| FY2024 | 2024-12-31 | (129.73M) | -24.4% |
| FY2023 | 2023-12-31 | (104.32M) | +2.0% |
| FY2022 | 2022-12-31 | (106.45M) | -47.3% |
| FY2021 | 2021-12-31 | (72.25M) | — |
Operating Income vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 operating income of -$196.46M is the 8th highest of the 10 companies compared; the peer median is -$110.76M.
- Its year-over-year change of -37.5% is the 8th highest of 10, against a peer median of -20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $116.26M | -83.8% | — | 11.5% | |
| LTM Mar 2026 | -$40.96M | +65.1% | — | 1.9% | |
| LTM Mar 2026 | -$81.23M | +25.7% | — | — | |
| LTM Mar 2026 | -$105.19M | +33.9% | — | 131.9% | |
| LTM Mar 2026 | -$110.76M | -23.4% | — | — | |
| LTM Mar 2026 | -$119.93M | -109.4% | — | — | |
| LTM Mar 2026 | -$179.55M | +11.7% | — | 203.5% | |
| LTM Mar 2026 | -$196.46M | -37.5% | — | — | |
| LTM Sep 2026 | -$218.18M | -20.6% | — | — | |
| LTM Jun 2026 | -$536.96M | -21.8% | — | — | |
| Peer median (excluding SLDB) | -$110.76M | -20.6% | — | 71.7% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| Weighted Avg Shares | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
| Weighted Avg Shares (Diluted) | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.